Evaluating Inebilizumab for treating NMDAR encephalitis
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease
This study is looking at how well and safely a medication called Inebilizumab works for people with NMDAR encephalitis, a serious brain condition, to help find better treatment options.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10701857 on NIH RePORTER |
What this research studies
This research investigates the effectiveness and safety of a medication called Inebilizumab for patients suffering from N-methyl-D-aspartate receptor (NMDAR) encephalitis, a serious autoimmune condition affecting the brain. The study involves a double-blind, randomized controlled trial, meaning that neither the participants nor the researchers know who is receiving the treatment or a placebo, to ensure unbiased results. Patients will be monitored for changes in their symptoms and any side effects, with a focus on understanding how the treatment impacts levels of specific autoantibodies in the cerebrospinal fluid. This approach aims to provide clearer insights into the best treatment strategies for this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 10-50 who have been diagnosed with NMDAR encephalitis and are experiencing significant psychiatric and neurological symptoms.
Not a fit: Patients who do not have NMDAR encephalitis or are outside the age range of 10-50 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with NMDAR encephalitis.
How similar studies have performed: Previous research has shown promise with similar treatments targeting autoimmune encephalitis, but this specific approach with Inebilizumab is relatively novel.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Clardy, Stacey Lynn — University of Utah
- Study coordinator: Clardy, Stacey Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.